🧬 Biotech Update: Reversing Age-Related Vision Loss
Telomir Pharmaceuticals (NASDAQ: TELO) has announced exciting new data from a peer-reviewed study on its leading compound, Telomir-Zn. Published in the International Journal of Molecular Sciences, the study reveals that this treatment successfully restored vision and repaired eye damage in models of Age-Related Macular Degeneration (AMD).
While Telomir is primarily testing this drug to treat advanced breast cancer, these new findings show its powerful potential to treat other major diseases linked to aging.
👁️ Key Findings from the Study
After 14 days of oral treatment, Telomir-Zn achieved remarkable results in retinal degeneration models:
- Restored Visual Function: Greatly improved central vision, light adaptation, and the ability to track moving objects.
- Rebuilt Eye Structure: Repaired and thickened damaged layers of the retina, protecting vital cells from oxidative stress.
- Reversed Cellular Aging: Increased telomere DNA content back toward healthy levels and restored youthful cellular patterns.
🔬 How It Works
Telomir-Zn safely balances metals (like zinc and copper) inside cells. This process stops specific enzymes from aging the cells, helping the body repair structural damage and protect against age-related decline. The mechanism works in Zebrafish, and is likely applicable in mammals and humans.
Telomir Pharmaceuticals is actively moving forward with its primary mission: a Phase 1/2 human clinical trial evaluating Telomir-Zn for advanced triple-negative breast cancer under an FDA-cleared application.
Read the official update on the Telomir Investor Relations Portal or review the full publication details via GlobeNewswire.
Frank Wilhelmi
Frank Wilhelmi - Retired/consultant electronic engineer researches and reports practical strategies for optimizing health and fitness into advanced age. “I have a passion for living life to the fullest, and helping others to do the same.” A rapidly growing body of knowledge now enables us to extend our health and fitness decades beyond popular expectations.